Clinical trials: Eye Cancer, Intraocular Melanoma
Uveal Melanoma
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.
- Trial name
- NCT01983748
- Testing
- Autologous Dendritic Cells loaded with autologous Tumor RNA
- Where
- 8 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Erlangen
Uveal Melanoma, Melanoma, Uveal
Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)
Study the efficacy of endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar to prevent neovascular glaucoma and secondary enucleation
- Trial name
- NCT02874040
- Testing
- Endoresection, Laser diode
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Institut Curie
Choroidal Melanoma, Diffuse
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.
- Trial name
- NCT01334008
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Curie
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Uveal Melanoma
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with…
- Trial name
- NCT00872391
- Testing
- Hypofractionated linear accelerator radiotherapy
- Where
- Austria
- Volunteers
- 155 people
- Sponsor
- Medical University of Vienna
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Psychoeducation for Uveal Melanoma
This clinical trial evaluates a video-based psychoeducational intervention for patients with uveal melanoma. Uveal melanoma (UM) is a rare intraocular cancer.
- Trial name
- NCT06075589
- Testing
- Education for Intervention, Best Practice
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Uveal Melanoma
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated…
- Trial name
- NCT07276386
- Testing
- Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ocular Melanoma
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues.
- Trial name
- NCT00346372
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ocular Melanoma
Definity for Ultrasound of Intraocular Tumors
The study will test the usefulness of a contrast agent to help image tumors in the eye. In this study, patients with eye melanoma who are going to have their eye removed, will have their eye imaged by ultrasound (sound waves)…
- Trial name
- NCT01930968
- Where
- United States
- Sponsor
- Emory University
Melanoma (Skin), Melanoma, Uveal
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.
- Trial name
- TebeMRD (NCT05315258)
- Testing
- Tebentafusp
- Where
- 10 sites in United Kingdom
- Volunteers
- 850 people
- Sponsor
- University of Oxford
Uveal Melanoma
The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma
The aim of the study is to identify genetic and epigenetic biomarkers in uveal melanoma, and to evaluate their diagnostic and prognostic role. In particular, the specific objectives are: 1.
- Trial name
- NCT05179174
- Testing
- blood sample examination
- Where
- 3 sites in Italy, Poland
- Volunteers
- 102 people
- Sponsor
- University of Catania
Uveal Melanoma
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
This is a Phase 2, single-arm study of nivolumab combined with ipilimumab in subjects with previously untreated, unresectable or metastatic uveal melanoma.
- Trial name
- GEM1402 (NCT02626962)
- Testing
- ipilimumab, Nivolumab
- Where
- 10 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus
Clinical and Histopathologic Characteristics of BAP1 Mutations
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen…
- Conditions
- Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM)
- Trial name
- NCT01773655
- Testing
- tumor specimens
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ocular Melanoma
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma.
- Trial name
- NCT00621439
- Testing
- Pegylated Interfon Alpha 2B
- Sponsor
- Emory University
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California